According to a recent report by Future Market Insights, the global antihistamine market is poised for significant growth, with a projected valuation of approximately USD 284.2 billion in 2023. The market is expected to exhibit a robust Compound Annual Growth Rate (CAGR) of 8.6% over the forecast period, potentially reaching USD 647.7 billion by 2033.
Antihistamines, widely used for treating allergic reactions, such as hay fever, rhinitis, and other conditions triggered by histamine release, have become integral to healthcare regimes worldwide. The increasing prevalence of allergies and asthma, coupled with the growing demand for over-the-counter (OTC) allergy relief products, is fueling the market’s expansion.
Stay Ahead with Market Trends: Access Your Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3138323935
Factors such as changing environmental conditions, rising air pollution, and growing awareness of allergic conditions are expected to continue to drive demand for antihistamines. Furthermore, innovations in drug formulations and delivery mechanisms, alongside the growing trend of self-medication, are contributing to the market’s positive growth outlook.
The market’s dynamic growth is also influenced by advancements in pharmaceutical research and the development of new, more effective antihistamine medications, including non-sedating formulations. As consumer preferences shift towards more convenient, non-drowsy treatment options, manufacturers are expected to focus on product innovation to capture a larger market share.
With strong growth prospects and an expanding consumer base, the global antihistamines market is set to witness substantial investment and continued innovation in the coming years. Industry stakeholders are encouraged to align their strategies with emerging consumer demands and regulatory trends to capitalize on this thriving market.
Key Takeaways from the Market Study
- In 2022, H-1 accounted for the highest market share of 9% in the antihistamine market.
- Over-the-counter antihistamines hold the highest market share of 3% in the type category.
- Tablets accounted for 0% of the market share in 2022. Due to the convenience and effectiveness of oral antihistamine drugs, this segment dominated the market with a 48.2 % market share.
- In 2022, the allergies segment led the indication category, accounting for 1% of the market.
- Hospital pharmacies dominated the distribution channel category with a market share of 9%.
- North America is considered the leading segment by region, with a market share of 0% at the end of the forecast period.
Market Competition:
The antihistamine market is highly fragmented in terms of antihistamine types and their different properties of allergies, skin conditions, product quality, and ethnicity. Market players are involved in developing advanced solutions, keeping various factors in mind that can be aligned with the customer’s requirements.
- In June 2022, Bayer Healthcare LLC received FDA approval for nonprescription Astepro, a nasal antihistamine, for both children above six years and adults.
- In July 2020, Alcon Vision LLC. received approval for the OTC Pataday Once Daily Relief Extra Strength (0.2% antihistamine) for the people in the United States as the first eye allergy itch drop that offers 24 hours of relief.
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report! https://www.futuremarketinsights.com/reports/antihistamine-market
Key Companies Profiled:
GlaxoSmithKline PLC.; Sanofi Consumer Healthcare; Himalaya Wellness Company; Sun Pharmaceutical Industries, Inc.; Bayer AG; Novartis AG; Cadila Pharmaceuticals; Bausch Health Companies Inc.; Alcon Vision LLC.; Merck & Co.; Dr. Reddy’s Laboratories, Ltd.; Viatris Inc.; Somerset Pharma, LLC; F. Hoffmann- La Roche Ltd.; Akorn Operating Company LLC; Teva Pharmaceutical Industries Ltd.; Speer laboratories; Glenmark Pharmaceuticals Limited; TerSera Therapeutics LLC; Pfizer Inc.; Morepen Laboratories Limited; Johnson & Johnson Services Inc.; Pharmaceutical Specialties Inc.; Proctor & Gamble
Key Market Segments Covered in Market Industry Research:
By Product:
- H-1 Blockers
- H-2 Blockers
By Type:
- Prescription-based
- Over-the-counter
By Dosage Forms:
- Tablets
- Capsules
- Liquids
- Other
By Route of Administration:
- Oral
- Parenteral
- Topical
By Indication:
- Allergies
- Urticaria
- Dermatitis
- Other
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
